Hayashida, Tetsu

写真a

Affiliation

School of Medicine, Department of Surgery (General and Gastroenterological Surgery) (Shinanomachi)

Position

Associate Professor

Related Websites

External Links
Page Top ▲

Career 【 Display / hide 】

  • 1998.05
    -
    Present

    慶應義塾大学医学部, 外科学, 研修医

  • 2000.05
    -
    Present

    慶應義塾大学医学部, 外科学, 助手（専修医）

  • 2001.05
    -
    Present

    慶應義塾大学医学部, 外科学, 助手

  • 2005.05
    -
    2008.05

    Harvard medical school & Massachusetts General Hospital, Department of Surgery, Cancer center, Research fellow

  • 2008.06
    -
    Present

    慶應義塾大学医学部, 外科学, 助教

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 1992.04
    -
    1998.03

    Keio University, 医学部

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, 慶應義塾大学, 2007

    ドメイン内插入融合蛋白(FGF-RNase fused protein)による3次元培養モデルにおける血管新生阻害効果

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 1998.05

  • 日本外科学会専門医, 2004.12

  • 日本がん治療認定医機構癌治療認定医, 2014.04

  • 日本乳癌学会認定位, 2014.04

  • 日本乳がん検診精度管理中央機構　検診マンモグラフィー読影認定医(A), 2015.06

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / General surgery and pediatric surgery

Page Top ▲

Research Keywords 【 Display / hide 】

  • Breast cancer

  • Breast surgery

Page Top ▲
 

Papers 【 Display / hide 】

  • A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.

    Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M

    Pathology international 69 ( 12 ) 715 - 720 2019.12

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1320-5463

  • THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis.

    Hayashi M, Kawakubo H, Fukuda K, Mayanagi S, Nakamura R, Suda K, Hayashida T, Wada N, Kitagawa Y

    The journal of gene medicine 21 ( 12 ) e3135 2019.12

    Joint Work,  ISSN  1099-498X

  • Intensive optimization and evaluation of global DNA methylation quantification using LC-MS/MS.

    Nakagawa T, Wakui M, Hayashida T, Nishime C, Murata M

    Analytical and bioanalytical chemistry 411 ( 27 ) 7221 - 7231 2019.10

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1618-2642

  • Magnetically Promoted Rapid Immunofluorescence Staining for Frozen Tissue Sections

    Onishi T., Matsuda S., Nakamura Y., Kuramoto J., Tsuruma A., Sakamoto S., Suzuki S., Fuchimoto D., Onishi A., Chikaki S., Kaneko M., Kuwahata A., Sekino M., Yasuno H., Hanyu N., Kurita T., Takei H., Sakatani T., Taruno K., Nakamura S., Hayashida T., Jinno H., Kusakabe M., Handa H., Kameyama K., Kitagawa Y.

    Journal of Histochemistry and Cytochemistry (Journal of Histochemistry and Cytochemistry)  67 ( 8 ) 575 - 587 2019.08

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00221554

    　View Summary

    © The Author(s) 2019. Current immunohistochemistry methods for diagnosing abnormal cells, such as cancer cells, require multiple steps and can be relatively slow compared with intraoperative frozen hematoxylin and eosin staining, and are therefore rarely used for intraoperative examination. Thus, there is a need for novel rapid detection methods. We previously demonstrated that functionalized fluorescent ferrite beads (FF beads) magnetically promoted rapid immunoreactions. The aim of this study was to improve the magnetically promoted rapid immunoreaction method using antibody-coated FF beads and a magnet subjected to a magnetic field. Using frozen sections of xenograft samples of A431 human epidermoid cancer cells that express high levels of epidermal growth factor receptor (EGFR) and anti-EGFR antibody-coated FF beads, we reduced the magnetically promoted immunohistochemistry procedure to a 1-min reaction and 1-min wash. We also determined the optimum magnetic force for the antibody reaction (from 7.79 × 10−15 N to 3.35 × 10−15 N) and washing (4.78 × 10−16 N), which are important steps in this technique. Furthermore, we stained paraffin-embedded tissue arrays and frozen sections of metastatic breast cancer lymph nodes with anti-pan-cytokeratin antibody-coated FF beads to validate the utility of this system in clinical specimens. Under optimal conditions, this ultra-rapid immunostaining method may provide an ancillary method for pathological diagnosis during surgery. (J Histochem Cytochem 58:XXX–XXX, 2010).

  • Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

    Watanuki R., Hayashida T., Kawai Y., Kikuchi M., Nakashoji A., Yokoe T., Toyota T., Seki T., Takahashi M., Kitagawa Y.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  24 ( 7 ) 807 - 814 2019.07

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  13419625

    　View Summary

    © 2019, Japan Society of Clinical Oncology. Purpose: In adjuvant settings of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, anthracycline-based chemotherapy followed by taxane and trastuzumab is a standard regimen. Recent studies have reported the use of anthracycline-free adjuvant chemotherapy in selected HER2-positive breast cancer patients. We conducted a single-center retrospective study to identify the characteristics of HER2-positive breast cancer patients for whom anthracyclines can be safely omitted. Methods: A total of 238 women were diagnosed with HER2-positive breast cancer and treated with neoadjuvant and/or adjuvant chemotherapy between January 1, 2008 and December 31, 2015 at Keio University Hospital. They were divided in two cohorts: an “anthracycline” cohort of 112 anthracycline-treated women and a “no anthracycline” cohort of 126 anthracycline-untreated women. Survival outcomes were estimated by Kaplan–Meier method. Results: The 3-year disease-free survival rates in the no-anthracycline and anthracycline cohorts were 91.3% and 93.1%, respectively (P = 0.692). After using a statistical method with inverse probability of treatment weighting to minimize the selection bias, no significant differences were observed between the two cohorts (adjusted hazard ratio for disease-free survival: 1.042; P = 0.909). Stratified by tumor size, no significant differences were observed between the two cohorts in the cT1N0 and cT2N0 subsets (P = 0.516 and P = 0.579, respectively). The recurrence rate was low among patients who achieved pathological complete response after receiving neoadjuvant chemotherapy with or without anthracyclines. Conclusion: Our study suggests that anthracyclines can be safely omitted in selected patients with HER2-positive breast cancer, who have cT1N0 or cT2N0 and achieved pathological complete response after receiving neoadjuvant chemotherapy.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 【いまだからこそ見直される乳房温存手術】傍乳輪wave-like incisionと全乳房皮下剥離を併用した整容性の高い乳房温存手術

    菊池 雅之, 林田 哲, 北川 雄光

    手術 (金原出版(株))  73 ( 12 ) 1659 - 1666 2019.11

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  0037-4423

  • 【がん遺伝子パネル検査の現状と展望】クリニカルシークエンスの現状と未来

    山口 茂夫, 林田 哲, 北川 雄光

    乳癌の臨床 ((株)篠原出版新社)  34 ( 5 ) 385 - 393 2019.10

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  0911-2251

  • MRI造影病変に対するVolume Navigation Systemの有用性の検討

    高橋 麻衣子, 関 朋子, 林田 哲, 北川 雄光

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  57回   O51 - 2 2019.10

    Joint Work

  • 機械学習法を用いた唾液メタボローム解析による乳癌スクリーニング

    村田 健, 柳澤 貴子, 栗原 俊明, 太田 紗菜, 金子 未来, 榎本 文芽, 冨田 勝, 杉本 昌弘, 砂村 眞琴, 林田 哲, 北川 雄光, 神野 浩光

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  57回   O52 - 3 2019.10

    Joint Work

  • 原発性乳癌骨転移症例の予後に関する検討

    関 朋子, 高橋 麻衣子, 林田 哲, 北川 雄光

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  57回   P123 - 1 2019.10

    Joint Work

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 肝癌に対する凍結融解壊死療（Cryoablation）

    Akatsu Tomotaka, Wakabayashi Gou, Tanabe Minoru, Ueda Masakazu, Shimazu Motohide, Aiura Kouichi, Kawachi Shigeyuki, Yoshida Masashi, Takigawa Yutaka, Hashimoto Takeo, Matsuura Yoshifumi, Abe Yuuta, Kido Hiromu, Hayashida Tetsu, Yagi Hiroshi, Itou Yasuhiro, Miyata Ryouhei, Kitajima Masaki

    第26回慶應外科フォーラム総会, 

    2003.01
    , 

    Oral presentation (general)

  • 当科における肝細胞癌に対する生体部分肝移植

    Akatsu Tomotaka, Shimazu Motohide, Wakabayashi Gou, Tanabe Minoru, Hoshino Ken, Kawachi Shigeyuki, Yoshida Masashi, Watanabe Toshihiko, Shibutani Shintarou, Hashimoto Takeo, Takigawa Yutaka, Shimojima Naoki, Abe Yuuta, Kaneda Munehisa, Kido Hiromu, Shintani Tsunehiro, Hayashida Tetsu, Yagi Hiroshi, Akiyoshi Takurin, Itou Yasuhiro, Inoue Fumihiko, Miyata Ryouhei, Morikawa Yasuhide, Kitajima Masaki

    第26回慶應外科フォーラム総会, 

    2003.01
    , 

    Oral presentation (invited, special)

  • c-kit陽性GISTに対しメシル酸イマチニブが著効を認めた1症例

    Hayashida Tetsu, Ueda Masakazu, Kawachi Shigeyuki, Tanabe Minoru, Aiura Kouichi, Wakabayashi Gou, Ootani Yoshihide, Shimazu Motohide, Kubota Tetsurou, Kitajima Masaki

    第64回日本臨床外科学会総会, 

    2002.11
    , 

    Oral presentation (general)

  • 非機能性膵内分泌腫瘍9例の検討

    Hayashida Tetsu, Aiura Kouichi, Itou Yasuhiro, Hashimoto Takeo, Kawachi Shigeyuki, Tanabe Minoru, Wakabayashi Gou, Shimazu Motohide, Ueda Masakazu, Kitajima Masaki

    第64回日本臨床外科学会総会, 

    2002.11
    , 

    Oral presentation (general)

  • 非機能性膵内分泌腫瘍9例の検討

    Hayashida Tetsu, Aiura Kouichi, Itou Yasuhiro, Hashimoto Takeo, Kawachi Shigeyuki, Tanabe Minoru, Wakabayashi Gou, Shimazu Motohide, Ueda Masakazu, Kitajima Masaki

    第64回日本臨床外科学会総会, 

    2002.11
    , 

    Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • BRCA2変異片アレル導入細胞株を用いたゲノム不安定性と発癌メカニズムの検証

    2024.04
    -
    2027.03

    基盤研究(C), Principal investigator

  • 人工知能による乳房超音波診断支援システムの精度向上と実用化の検討

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • HOXB9 expression in breast cancer predicts efficacy of bevacizumab treatment

    2014.04
    -
    2017.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

    　View Summary

    Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor progression and has recently been recognized as a strong angiogenic factor in breast cancer progresson. This study aimed to investigate the role of HOXB9 in tumorigenesis and angiogenesis. Bevacizumab, an anti-VEGF antibody, remarkably suppressed tumor proliferation by inhibiting angiogenesis in HOXB9-overexpressing xenografts. HOXB9 promotes the secretion of angiogenic factors, including VEGF, to induce tumor proliferation through microenvironmental communication via IL6 signaling; moreover, silencing of VEGF or IL6 terminates microenvironmental crosstalk. Thus, HOXB9 and IL6 may be surrogate markers for bevacizumab treatment in breast cancer.

Page Top ▲

Awards 【 Display / hide 】

  • The 8th International Symposium On Cancer Research and Therapy, Subsidy Award

    2013.11

  • 第51回日本癌治療学会　最優秀演題賞

    2013.10, 日本癌治療学会

  • 第22回広島がんセミナー　最優秀演題賞

    2011.10

  • 第19回日本がん転移学会学術総会　最優秀演題賞

    2011.06, 日本がん転移学会

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, SURGERY

    2024

  • LECTURE SERIES, SURGERY

    2023

  • LECTURE SERIES, SURGERY

    2022

  • LECTURE SERIES, SURGERY

    2021

  • PATHOPHYSIOLOGY FOR ACUTE CARE

    2020

display all >>

Page Top ▲